Adamis Pharmaceuticals Corp ADMP shares are trading higher on Monday.
The company announced a license to commercialize Tempol, a patented investigational drug for the treatment of coronavirus and respiratory disease.
Adamis Pharmaceuticals is a specialty biopharmaceutical company. It is focused on developing and commercializing products in various therapeutic areas, including respiratory disease, allergy, and opioid overdose.
Adamis shares were trading up 11.81% at 66 cents at time of publication on Monday. The stock has a 52-week high of $1.57 and a 52-week low of 27 cents.
Related Links:
UK Clears Gilead's Remdesivir For Some Coronavirus Patients
Gilead Analysts See Questionable Commercial Opportunity For Coronavirus Candidate Remdesivir
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
